Check for updates

OPEN ACCESS

EDITED BY Ashu Johri, Independent Researcher, New York, United States

REVIEWED BY

Viridiana Alcantara-Alonso, Imperial College London, United Kingdom Waldemar Kanczkowski, Technical University Dresden, Germany

*CORRESPONDENCE Vinicius Frias Carvalho Viniciusfrias@hotmail.com

RECEIVED 23 September 2024 ACCEPTED 07 January 2025 PUBLISHED 27 January 2025

CITATION

Chaves AS, Ventura RD, Pacini MF, Magalhães NS, Silva PMRe, Martins MA, Pérez AR and Carvalho VF (2025) Activation of the Nrf2/HO-1 pathway restores Nacetylcysteine-induced impairment of the hypothalamus-pituitary-adrenal axis negative feedback by up-regulating GR α expression and down-regulating GR β expression into pituitary glands. *Front. Endocrinol.* 16:1500630. doi: 10.3389/fendo.2025.1500630

COPYRIGHT

© 2025 Chaves, Ventura, Pacini, Magalhães, Silva, Martins, Pérez and Carvalho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Activation of the Nrf2/HO-1 pathway restores N-acetylcysteine-induced impairment of the hypothalamus-pituitary-adrenal axis negative feedback by up-regulating GR α expression and down-regulating GR β expression into pituitary glands

Amanda Silva Chaves¹, Raíssa Duarte Ventura¹, Maria Florencia Pacini², Nathalia Santos Magalhães¹, Patrícia Machado Rodrigues e Silva¹, Marco Aurélio Martins¹, Ana Rosa Pérez² and Vinicius Frias Carvalho^{1,3,4,5*}

¹Laboratory of Inflammation, Center for Research, Innovation, and Surveillance in Covid-19 and Health Emergencies, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, ²Institute of Clinical and Experimental Immunology (IDICER-CONICET UNR), Rosario, Argentina, ³National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, ⁴Rio de Janeiro Research Network on Neuroinflammation (RENEURIN), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, ⁵INOVA-IOC Network on Neuroimmunomodulation, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

We previously showed that antioxidants induced an impairment of negative feedback of the hypothalamus-pituitary-adrenal (HPA) axis in rats, in parallel to a down-regulation of the glucocorticoid receptor (GR) and nuclear factor erythroid 2-related factor 2 (Nrf2) expression in the pituitary gland. This study evaluated the role of the Nrf2-heme-oxygenase-1 (HO-1) pathway on the impairment of the negative feedback of the HPA axis induced by Nacetylcysteine (NAC). Male Swiss-Webster mice were orally supplemented with NAC for 5 consecutive days. The Nrf2-HO-1 pathway activator cobalt protoporphyrin IX (CoPPIX) was injected intraperitoneally on days 2 and 5 after the starting of NAC supplementation. NAC reduced the expression of Nrf2 in the pituitary of mice. Furthermore, NAC induced adrenal enlargement and hypercorticoidism, along with a decrease in the $GR\alpha$ expression and an increase of GR β expression in the pituitary gland. Treatment with CoPPIX reduced adrenal enlargement, systemic corticosterone levels, and $GR\beta$ expression in the pituitary gland of mice supplemented with NAC, besides increasing the expression of $GR\alpha$. CoPPIX treatment also restored the failure in the negative feedback of the HPA axis induced by NAC. In conclusion, these

findings showed that NAC reduced the Nrf2-HO-1 pathway activation in the pituitary gland, in a mechanism probably related to a local downregulation of GR α and an up-regulation of GR β , leading to a failure of negative feedback of the HPA axis and consequently to the hyperactivity of this neuroendocrine axis.

KEYWORDS

antioxidants, glucocorticoid, GR isoforms, HPA axis, Nrf-2

1 Introduction

The hypothalamus-pituitary-adrenal (HPA) axis is a neuroendocrine system regulated by the circadian cycle and stress (1). Under normal conditions, glucocorticoids, the final product of the HPA axis, are produced through the activation of the adrenocorticotropic hormone (ACTH)-melanocortin receptor 2 (MC2R) signaling pathway in the adrenal glands (2). Chronic activation of the HPA axis can have damaging effects on immune, cardiovascular, metabolic, and neural functions, increasing the risk of immune system dysfunction, mood disorders, and metabolic and cardiovascular diseases (3). To prevent these deleterious effects of chronic hypercortisolism, the HPA axis function is controlled by a glucocorticoid-dependent negative feedback system that is essential for ending the stress response. In corticotroph cells, the activation of glucocorticoid receptor (GR)- α isoform by glucocorticoids is crucial for the negative feedback of the HPA axis (4).

Reactive oxygen species (ROS), such as superoxide, hydroxyl radicals, and hydrogen peroxide, are produced by oxygen reduction (5). As the overproduction of ROS is toxic to cells, its synthesis is finely controlled by endogenous antioxidant enzymes (6). ROS are known to act as signaling molecules in physiological processes, activating a defensive response, including nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase (HO)-1 pathway, which appears to protect the organism from subsequent higher stresses (7–9). Furthermore, the loss of Nrf2 activity in mouse fibroblasts, hepatocytes, and liver cells disrupts local circadian rhythms (10). Although the disruption of local circadian rhythms can increase pituitary gland activation (11, 12), the effect of Nrf2 on the negative feedback of the HPA axis is unclear.

In previous works, we demonstrated that oral supplementation with antioxidants induces hyperactivity of the HPA axis in mice and rats (13, 14). The antioxidant-induced hyperactivation of this axis was related to overexpression of MC2R and steroidogenic machinery in the adrenal gland, along with a down-regulation of GR in the pituitary gland, leading to a failure of the negative feedback mechanism of the HPA axis. We also showed that N-acetylcysteine (NAC) reduced the expression of Nrf2 and HO-1 in the pituitary gland of rats (13). In this study, we evaluated the effect of Nrf2/HO-1 pathway activator cobalt protoporphyrin IX (CoPPIX) (15, 16) on the NAC-induced hypercortisolism in healthy mice.

2 Materials and methods

2.1 Animals

Following the guidelines of the Committee on Use of Laboratory Animals of Oswaldo Cruz Institute (CEUA-IOC/ Fiocruz, license L-027/2016 and L-004/2024), male Swiss-Webster mice obtained from Science and Technology in Biomodels Institute of Fiocruz were used. Mice aged between 4 and 6 weeks were housed in groups of five in temperature-, humidity-, and light-controlled (12 h light: 12 h darkness cycle) colony room. Mice were given access *ad libitum* to food and water.

2.2 Antioxidant supplementation and treatment

The mice were supplemented with antioxidant N-acetyl cysteine (NAC) (150 mg/kg body weight) (Sigma Chemical Co., Saint Louis, MO, USA) (17-19) by gavage once a day, during five consecutive days. Control mice received an equal volume of vehicles (sterile saline 0.9%). The mice were treated concomitantly with Co (III) Protoporphyrin IX chloride (Nrf2-HO-1 pathway activator -CoPPIX) (10 mg/kg body weight, i.p.) (Co654-9, Frontier Scientific, Inc., Logan, UT, USA) (14) on days 2 and 5 after the start of NAC supplementation (Figure 1A). CoPPIX was diluted with NaOH 0.1N (10% final volume) (Merck, Rio de Janeiro, Brazil), and then, HCl 1N (Merck) to obtain a solution with pH 7.4. Untreated mice received an equal volume of vehicles. To analyze corticoid-induced negative feedback sensitivity, a group of animals received dexamethasone (20 µg/kg body weight, s.c.) (Sigma Chemical Co.) 1h before the euthanasia. Control mice were treated s.c. with sterile saline 0.9%. All analyses were performed 24 hours after the last supplementation with NAC. All solutions were freshly prepared

Abbreviations: ACTH, adrenocorticotrophic hormone; CoPPIX, cobalt protoporphyrin IX; GR, glucocorticoid receptor; HCL, hydrogen chloride; HO-1, heme oxygenase-1; HPA, hypothalamus-pituitary-adrenal axis; MC2R, melanocortin-2 receptor; NAC, N-acetylcysteine; NAOH, sodium hydroxide; Nfr2, nuclear factor erythroid 2-related factor 2; qPCR, polymerase chain reaction; ROS, reactive oxygen species.

immediately before use. To analyze whether the effect of NAC is sustainable after the interruption of the supplementation, we administered NAC by gavage once a day, during five consecutive days, and analyzed plasma corticosterone levels 24h and 15 days after the last supplementation with NAC.

2.3 Evaluation of mRNA expression of GR α , GR β , and Nfr-2 by real time PCR

Total RNA was isolated from adrenal and pituitary glands using TRI Reagent[®] and followed reverse-transcribed to cDNA using the RevertAid Reverse Transcriptase (Thermo Fisher Scientific, Waltham, USA). Real-time PCR was performed with the

StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, USA) using a Mix (5x HOT FIREPol[®] EvaGreen[®] qPCR Mix Plus with ROX; Solis BioDyne, Estonia) according to the manufacturer's instructions. The amplification program included an initial activation step at 95°C for 15min, followed by denaturation at 95°C for 15s, annealing between 59°-62°C and finally elongation at 72°C for 20s, for 40 cycles. Fluorescence was measured after each extension step, and the specificity of amplification was evaluated by melting curve analysis. The housekeeping gene GADPH was used as a control to normalize RNA samples. Relative gene expression levels were calculated using the $\Delta\Delta C_T$ method (20). Amplification efficiencies were identical or similar between genes of interest and controls. Primers were designed in our laboratory and purchased from Eurofins



FIGURE 1

CoPPIX increases the under-expression of Nrf2 and HO-1 in the pituitary glands of mice supplemented with NAC. (A) *In vivo* protocol. Mice were supplemented with NAC (150 mg/Kg, gavage) daily for 5 consecutive days and treated with CoPPIX (10 mg/Kg, i.p.) on days 2 and 5 after the starting of oral supplementation with the antioxidant. Non-supplemented animals received an equal amount of vehicles (NaOH 0.1N and HCl 1N, pH = 7.4, i.p.), and analyses were performed 24 h after the last supplementation with NAC and/or treatment with CoPPIX. (B, C) Nrf2 gene expression in adrenal and pituitary glands of mice, measured by qPCR, respectively. Data are expressed as the mean \pm SEM. *P < 0.05. CoPPIX, Cobalt protoporphyrin IX; HO-1, Heme-oxygenase-1; NAC, N-acetylcysteine; Nrf2, Nuclear factor erythroid 2-related factor 2.

Genomics Scientific, Inc. (Louisville, USA) or Invitrogen Thermo Fisher Scientific, Inc. (Carlsbad, USA). The primer used were: i) GAPDH - forward: AGCAATGCATCCTGCACCACCA; reverse: ATGCCAGTGAGCTTCCCGTTCA; ii) GR α - forward: AAAGAG CTAGGAAAAGCCATTGTC; reverse: TCAGCTAACATCTCTG GGAATTCA; iii) GR β - forward: AAAGAGCTAGGAAAAGCCA TTGTC; reverse: CTGTCTTTGGGCTTTTGAGATAGG; iv) Nrf2 - forward: TAGATGACCATGAGTCGCTTG; reverse: GCCAAACTTGCTCCATGTCC.

2.4 Western blot analysis

The pituitary glands were homogenized in RIPA buffer containing protease and phosphatase inhibitor cocktails, and then, the protein content was quantified by the BCA method (21). 60 µg total protein/lane was resolved on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, for evaluation of GR protein expression, and afterward electrotransferred through a semi-dry transfer apparatus (Trans-Blot SD; Bio-Rad, Hercules, CA, USA) to a nitrocellulose membrane. Subsequently, the membrane was blocked with a solution containing Tris-buffered saline, 5% bovine serum albumin, and 0.1% Tween 20, pH 7.4 (TBST), for 90 minutes at room temperature. Then, the membrane was incubated with a primary antibody dissolved in the blocking solution overnight at 4°C. Primary antibody against anti-GR (1:200; Santa Cruz Biotechnology) was used. The housekeeping anti-βactin (1:1000; Santa Cruz Biotechnology) was used as the standard. Afterward, the membrane was incubated with an HRP conjugated secondary antibody polyclonal anti-rabbit IgG HRP (1:10.000, Invitrogen ThermoFisher Scientific, MA, USA), or monoclonal anti-mouse IgGs HRP (1:1000, R&D System, Minneapolis, MN, USA) for 60 minutes at room temperature, and the immunocomplexes were visualized by using a ChemiDoc MP Imaging System 6.0.1 (Bio-Rad Laboratories, Inc, Hercules, CA, USA). Then, the band density measurements were analyzed by Image Lab software version 6.1.0 (Bio-Rad Laboratories, Inc). The description of all the antibodies used is in Supplementary Table S1.

2.5 Hormone quantification

After euthanasia (ketamine 140 mg/Kg and xylazine 20 mg/Kg i.p.) of mice, during nadir (08:00h) of the circadian rhythm (21). Blood was immediately collected from the abdominal aorta with heparinized (40 U/ml) saline, centrifuged for 20 min at 1000 x g, and stored at -20°C until use. The ELISA kit detected plasma corticosterone levels following the manufacturer's guidelines (Cayman Chemical, 501320, Cedarlane Labs, Canada).

2.6 Statistical analysis

The data are reported as the mean ± standard error of the mean (SEM). Data distribution was assessed by Kolmogorov-Smirnov. Data with normal distribution was statistically analyzed by one-way

ANOVA followed by Tukey's multiple comparison *post-hoc* test. Data without normal distribution was evaluated by Kruskall-Wallis followed by the U-Mann Whitney test. All statistical analysis was performed with GraphPad Prism 8 software. Probability values (p) of 0.05 or less were considered significant. Determining if the frequency distribution of a given data set follows a normal distribution or not is among the first steps of data analysis.

3 Results

3.1 CoPPIX restores NAC-induced underexpression of Nrf-2 in the pituitary gland of mice

Supplementation with NAC (Figure 1A) did not alter the mRNA expression of Nrf2 in adrenal glands compared to non-supplemented mice (Figures 1B); however, it reduced the mRNA expression of Nrf2 in the pituitary glands (Figures 1C).

3.2 CoPPIX reduces adrenal enlargement and hypercorticoidism induced by NAC supplementation

NAC supplementation did not affect the overall body weight of mice (Figure 2A), but induced adrenal enlargement, which was evidenced by an increase in the adrenal weight and the adrenal-tobody weight ratio (Figures 2B, C, respectively) compared to nonsupplemented mice. However, the treatment with CoPPIX prevented the adrenal enlargement observed in NAC-supplemented mice without modifying the body weight (Figures 2A-C). CoPPIX did not alter these readouts in non-supplemented mice. In addition, NAC increased circulating corticosterone levels compared to nonsupplemented mice (Figure 2D). Remarkably, this change was sensitive to CoPPIX treatment, as evidenced by conditions in which the CoPPIX did not alter this parameter in nonsupplemented mice (Figure 2D).

3.3 CoPPIX restored NAC-induced failure in the negative feedback of the HPA axis by increasing the expression of GR α in the pituitary gland of mice

Dexamethasone reduced plasma corticosterone levels in nonsupplemented mice, however; it failed to inhibit this readout in NAC-supplemented mice, indicating an impairment in the negative feedback of the HPA axis due to NAC supplementation in mice. Notably, CoPPIX restored dexamethasone's ability to reduce plasma corticosterone levels in NAC-supplemented mice, while it did not affect this parameter in non-supplemented mice (Figure 3A). We also demonstrated that NAC decreased GR protein expression in the pituitary gland of mice, which was sensitive to CoPPIX treatment (Supplementary Figure S1). Furthermore, CoPPIX did not modify this readout in nonsupplemented mice (Figure 3B). In addition, NAC significantly reduced GR α expression (Figure 3C) and increased GR β expression in the pituitary gland of mice (Figure 3D). Treatment with CoPPIX significantly increased GR α expression and decreased GR β expression in the pituitary gland of mice supplemented with NAC (Figures 3C, D, respectively). CoPPIX treatment did not significantly alter GR α and GR β in non-supplemented mice.

3.4 NAC increases plasma corticosterone levels in mice even after discontinuing supplementation for 15 days

We observed that dietary supplementation with NAC (Figure 4A) significantly increased plasma corticosterone levels in mice 24h (Figure 4B) as well as 15 days (Figure 4C) after the last administration of the antioxidant with the same magnitude of the response (3.5-fold and 3.4-fold, respectively).

4 Discussion

This study investigated the effect of Nrf2/HO-1 pathway activator CoPPIX on NAC-induced impairment of HPA axis negative feedback in healthy mice. We found that CoPPIX treatment increased the expression of Nrf2 in the pituitary gland of NAC-supplemented mice. In addition, CoPPIX treatment inhibited NAC-induced hypercorticoidism in healthy mice, parallel to a reduction in adrenal enlargement. The decrease in the corticosterone production in the adrenal glands of NACsupplemented mice treated with CoPPIX was correlated with an improvement in the negative feedback of the HPA axis, as well as up-regulation of GR α and downregulation of GR β expression in the pituitary gland. Our findings suggest that the impairment of the negative feedback of the HPA axis induced by NAC supplementation is probably due to an imbalance in GR isoform expression in the pituitary gland, caused by local downregulation of the Nrf2-HO-1 pathway.



CoPPIX reduces adrenal enlargement and plasma corticosterone levels observed in mice supplemented with NAC. Mice were supplemented with NAC (150 mg/Kg, gavage) daily for 5 consecutive days and treated with CoPPIX (10 mg/Kg, i.p.) on days 2 and 5 after the starting of oral supplementation with the antioxidant. Non-supplemented animals received an equal amount of vehicle (NaOH 0.1N and HCl 1N, pH = 7.4, i.p.), and analyses were performed 24 h after the last supplementation with NAC and/or treatment CoPPIX. (A) Body weight of mice. (B) Adrenal weight of mice. (C) The ratio between adrenal and body weight. (D) Plasma quantification of corticosterone levels. Data are expressed as the mean \pm SEM. *P < 0.05. CoPPIX, Cobalt protoporphyrin IX; NAC, N-acetylcysteine.



Currently, many people incorporate antioxidants into their daily regimen as a proactive measure to combat the effects of aging, including the development of age-related diseases (22, 23). Nevertheless, numerous clinical trials evaluating the efficacy and safety of antioxidant supplementation have failed to show beneficial readouts and, in some cases, have suggested an increase in overall mortality rates (24-26). Previously, we showed that supplementation with two different antioxidants, NAC and vitamin E, increased plasma corticosterone levels in mice and rats (13). Additionally, NAC was shown to abolish the ability of exogenous glucocorticoids to perform negative feedback on the HPA axis in rats, alongside a decrease in the expression of GR, Nrf2, and HO-1 in the pituitary gland (13). However, the causal effect of the downregulation of the Nrf2-HO-1 pathway on NAC-induced impairment of the HPA axis negative feedback remains unknown. Therefore, we hypothesized that activating the Nrf2-HO-1 pathway by CoPPIX in the pituitary of NAC-supplemented mice could improve the HPA axis negative feedback failure observed in these animals.

Initially, we confirmed our previous findings in rats and demonstrated that NAC supplementation also reduced the expression of Nrf2 in the pituitary gland of healthy mice, even with a shorter supplementation period. Our data agree with the literature that showed that treatment with NAC reduced the expression of Nrf2 and HO-1 in non-stimulated human umbilical vein cells (HUVECs) and C2C12 myotube cells and AuNP-induced up-regulation of Nrf2-HO-1 pathway in human vascular endothelial cells (27–29).

To evaluate whether activation of the Nrf2-HO-1 pathway in the pituitary of NAC-supplemented mice could improve the negative feedback of the HPA axis, we first evaluated if CoPPIX treatment could reduce the hypercorticoidism observed in these animals. First, we confirmed that supplementation with NAC increased the plasma corticosterone levels in mice. Although antioxidant treatment decreases corticosterone levels in several models of diseases, including brain oxidative stress induced by lipopolysaccharide and streptozotocin-induced diabetes in rats (30, 31), we showed that



physiological ROS act as messenger molecules in pituitary cells of healthy mice and are vital to their homeostasis maintenance. Furthermore, we showed that CoPPIX treatment inhibited both NAC-induced adrenal enlargement and hypercorticoidism in mice. These findings suggest that reduced activation of the Nrf2-HO-1 signaling pathway in the pituitary is involved in the hyperactivity of the HPA axis induced by NAC supplementation. While we believe that CoPPIX does not act directly on the adrenal glands - since NAC supplementation did not alter Nrf2 mRNA expression in the adrenals - we cannot entirely rule out the possibility that CoPPIX restored NAC-induced a reduction in the MC2R expression in the adrenal gland and, consequently, the adrenal insensitivity to ACTH stimulation. In fact, the downregulation of HO-1 expression in adrenocortical cells has been shown to increase ACTH-induced progesterone steroidogenesis in vitro (32), indicating that the Nrf2-HO-1 pathway plays a crucial role in adrenal steroidogenesis.

Since CoPPIX inhibited NAC-induced hypercorticoidism and restored the expression of Nrf2 and HO-1 in the pituitary gland of mice, we further evaluated the effect of Nrf2-HO-1pathway activation on the functioning of the negative feedback of the HPA axis. For this, we assessed the sensitivity of the HPA axis to negative feedback induced by the synthetic exogenous glucocorticoid dexamethasone in NAC-supplemented mice treated or not with CoPPIX. Dexamethasone reduced circulating corticosterone levels in non-supplemented mice, but did not affect plasma glucocorticoid levels in NAC-supplemented mice, indicating that NAC impairs the negative feedback of the HPA axis. Interestingly, CoPPIX treatment significantly reduced plasma corticosterone levels in dexamethasone-treated and NAC-supplemented mice, indicating that CoPPIX restored the ability of glucocorticoids to perform negative feedback on the HPA axis.

It is well known that the inhibition of stressor-evoked HPA axis responses at the pituitary level is mediated by the activation of GR (33, 34). Furthermore, NAC reduces the expression of GR in the hypothalamus of mice on a high-cholesterol diet (35) and in the pituitary of healthy rats (13). As expected, we showed that NAC significantly reduced GR protein expression in healthy mice's pituitary. Treatment with CoPPIX significantly increased the density of GR in this gland of mice supplemented with NAC, strongly confirming that the downregulation of the Nrf2-HO-1 pathway has a causal relationship with the failure of the negative feedback of the HPA axis observed in mice supplemented with NAC. Among the isoforms of GR produced by alternative splicing GRa and GR β stand out. Unlike GR α , which is the classic receptor responsible for glucocorticoid actions, GRB cannot bind to glucocorticoids. Nevertheless, $GR\beta$ forms a heterodimer with $GR\alpha$ and exerts a dominant-negative effect on GR α -mediated transcription (36-38). Although Otto et al. described that GRB is not conserved across species and its physiological significance in humans appears questionable, they only evaluated the exons 7, 8, and 9 of the GR loci (39). Currently, it is well known that the mGR β isoform arises from a distinct alternative splicing mechanism utilizing intron 8,

rather than exon 9 as in humans, and that this isoform showed the same properties reported for human GR β (40, 41). Interestingly, dietary supplementation with NAC significantly reduced the expression of GRa mRNA and increased the expression of GRB mRNA in the pituitary gland of healthy mice. This data can explain the exact mechanism by which supplementation with NAC completely impairs the HPA axis' negative feedback, even with a slight but significant reduction in the expression of total GR protein levels. Treatment with CoPPIX increased the expression of GRa mRNA in the pituitary gland of NAC-supplemented mice, however, strongly decreased the expression of GRB mRNA. Our data showed that the activation of the Nrf2-HO-1 pathway restores the negative feedback of the HPA axis of mice supplemented with NAC by upregulating the expression of the receptor responsible for the glucocorticoid actions, together with a downregulation of the expression of the receptor responsible by the impairment of GRamediated activities. In addition, for the first time, we showed that the Nrf2-HO-1 pathway can regulate direct or indirectly the expression of GR isoforms, therefore, our findings contribute novel insights into GR potential regulatory mechanism. Nevertheless, further studies will be required to delineate the exact intracellular pathways involved with the Nrf2/HO-1 pathway-induced glucocorticoid receptor gene expression modulation. Although we strongly believe that activation of the Nrf2-HO-1 pathway in mice supplemented with NAC restores HPA axis negative feedback by modulating the expression of GR isoforms in the mouse pituitary, it is imperative to emphasize that an important limitation of the work is the lack of circulating ACTH levels measurement. We can mainly rule out that NAC supplementation might reduce corticosterone metabolism in the liver and intestine (42), and that CoPPIX treatment might be preventing this possible extra HPA axis effect of NAC supplementation.

We also evaluated the effect of the discontinuation of the supplementation of NAC on the plasma corticosterone levels of mice to evaluate whether NAC-induced downregulation of the HPA axis negative feedback is part of an adaptation period or if this can have a long-lasting effect on the HPA axis stress response. We showed that even after we stopped the dietary supplementation of mice with NAC for 15 days, they showed the same magnitude of increase in circulating corticosterone levels when compared to mice who did not have their supplementation interrupted. Therefore, we can hypothesize that the supplementation of NAC in mice for only 5 days induces a sustainable alteration of the control of glucocorticoid production for at least 15 days. One limitation of our study was that we used only male mice to investigate the effect of NAC on the hyperactivity of the HPA axis in healthy animals, and the effects of NAC on HPA axis function in females should also he considered

The CoPPIX enhances cellular antioxidant defenses and reduces the production of ROS by inducing the HO-1 signaling pathway, protecting cells from oxidative damage (43). Despite the promising preclinical data, the clinical development of CoPPIX as an antioxidant therapy is in its early stages. Further detailed preclinical and clinical studies are necessary to fully understand the therapeutic potential and safety use of CoPPIX in humans. Moreover, the exploration of CoPPIX and other Nrf2-HO-1 activators holds the potential for developing novel therapeutic strategies for oxidative stress-related diseases (44, 45).

In summary, our results indicate that NAC-induced hyperactivity of the HPA axis in mice is related to the reduction of the activity of the Nrf2-HO-1 pathway in the pituitary gland. This effect seems to be caused by a reduced GR α mRNA and an increased GR β mRNA transcription, which could lead to a subsequent impairment of the negative feedback of the HPA axis. In addition, the activation of the Nrf2-HO-1 pathway with CoPPIX normalizes the dysregulation in the pituitary gland induced by NAC supplementation and, consequently, stabilizes the negative feedback of the HPA axis after dexamethasone suppression test.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The animal study was reviewed and approved by committee on Use of Laboratory Animals of the Oswaldo Cruz Institute (CEUA-IOC/FIOCRUZ, license L-027/2016 and L-004/2024). The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

AC: Conceptualization, Formal analysis, Methodology, Writing – original draft. RV: Formal analysis, Methodology, Writing – review & editing. MP: Formal analysis, Methodology, Writing – review & editing. NM: Formal analysis, Methodology, Writing – review & editing. PS: Formal analysis, Funding acquisition, Resources, Writing – review & editing. MM: Formal analysis, Funding acquisition, Resources, Writing – review & editing. AP: Formal analysis, Resources, Writing – review & editing. VC: Conceptualization, Formal analysis, Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was financial supported by Fundação Carlos Chagas de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Programa de

Auxílio à Pesquisa (PAPESVI/FIOCRUZ), Programa INOVA FIOCRUZ, and Ministério da Saúde, Brazil. The funding agencies had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

References

1. Russell G, Lightman S. The human stress response. Nat Rev Endocrinol. (2019) 15:525-34. doi: 10.1038/s41574-019-0228-0

2. Dores RM, Londraville RL, Prokop J, Davis P, Dewey N, Lesinski N. MOLECULAR EVOLUTION OF GPCRS: melanocortin/melanocortin receptors. J Mol Endocrinol. (2014) 52:T29-42. doi: 10.1530/JME-14-0050

3. Sheng JA, Bales NJ, Myers SA, Bautista AI, Roueinfar M, Hale TM, et al. The hypothalamic-pituitary-adrenal axis: development, programming actions of hormones, and maternal-fetal interactions. *Front Behav Neurosci.* (2021) 14:601939. doi: 10.3389/fnbeh.2020.601939

4. Harno E, Gali Ramamoorthy T, Coll AP, White A. POMC: the physiological power of hormone processing. *Physiol Rev.* (2018) 98:2381-430. doi: 10.1152/ physrev.00024.2017

5. Forman HJ, Augusto O, Brigelius-Flohe R, Dennery PA, Kalyanaraman B, Ischiropoulos H, et al. Even free radicals should follow some rules: A Guide to free radical research terminology and methodology. *Free Radic Biol Med.* (2015) 78:233–5. doi: 10.1016/j.freeradbiomed.2014.10.504

6. Hu L, Zhang Y, Miao W, Cheng T. Reactive oxygen species and nrf2: functional and transcriptional regulators of hematopoiesis. *Oxid Med Cell Longev.* (2019) 2019:1–11. doi: 10.1155/2019/5153268

 Abdelnaser M, Alaaeldin R, Attya ME, Fathy M. Modulating Nrf-2/HO-1, apoptosis and oxidative stress signaling pathways by gabapentin ameliorates sepsisinduced acute kidney injury. *Naunyn Schmiedebergs Arch Pharmacol.* (2024) 397:947– 58. doi: 10.1007/s00210-023-02650-y

8. Saha S, Buttari B, Panieri E, Profumo E, Saso L. An overview of nrf2 signaling pathway and its role in inflammation. *Molecules*. (2020) 25:5474. doi: 10.3390/molecules25225474

9. Gough DR, Cotter TG. Hydrogen peroxide: a Jekyll and Hyde signalling molecule. *Cell Death Dis.* (2011) 2:e213–3. doi: 10.1038/cddis.2011.96

10. Wible RS, Ramanathan C, Sutter CH, Olesen KM, Kensler TW, Liu AC, et al. NRF2 regulates core and stabilizing circadian clock loops, coupling redox and timekeeping in Mus musculus. *Elife*. (2018) 7:153. doi: 10.7554/eLife.31656

11. Zhang D, Heaney AP. Nuclear receptors as regulators of pituitary corticotroph pro-opiomelanocortin transcription. *Cells.* (2020) 9:900. doi: 10.3390/cells9040900

12. Tsukamoto-Yamauchi N, Terasaka T, Iwasaki Y, Otsuka F. Interaction of pituitary hormones and expression of clock genes modulated by bone morphogenetic protein-4 and melatonin. *Biochem Biophys Res Commun.* (2015) 459:172–7. doi: 10.1016/j.bbrc.2015.02.100

13. Prevatto JP, Torres RC, Diaz BL, e Silva PMR, Martins MA, Carvalho VF. Antioxidant treatment induces hyperactivation of the HPA axis by upregulating ACTH receptor in the adrenal and downregulating glucocorticoid receptors in the pituitary. *Oxid Med Cell Longev.* (2017) 2017:159–86. doi: 10.1155/2017/4156361

14. Ventura RD, Chaves AS, Magalhães NS, Gonzalez FB, Pacini MF, Pérez AR, et al. Activation of PPAR γ reduces N-acetyl-cysteine -induced hypercorticoidism by down-regulating MC2R expression into adrenal glands. *Free Radic Biol Med.* (2020) 156:137–43. doi: 10.1016/j.freeradbiomed.2020.06.008

15. Shan Y, Lambrecht RW, Donohue SE, Bonkovsky HL, Shan Y, Lambrecht RW, et al. Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. *FASEB J.* (2006) 20:2651–3. doi: 10.1096/fj.06-6346fje

16. Ahuja M, Ammal Kaidery N, Attucks OC, McDade E, Hushpulian DM, Gaisin A, et al. Bach1 derepression is neuroprotective in a mouse model of Parkinson's disease. *Proc Natl Acad Sci.* (2021) 118:187. doi: 10.1073/pnas.2111643118

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2025. 1500630/full#supplementary-material

17. Muniroh M, Gumay AR, Indraswari DA, Bahtiar Y, Hardian H, Bakri S, et al. Activation of MIP-2 and MCP-5 expression in methylmercury-exposed mice and their suppression by N-acetyl-L-cysteine. *Neurotox Res.* (2020) 37:827–34. doi: 10.1007/s12640-020-00174-4

18. Chen S, Ren Q, Zhang J, Ye Y, Zhang Z, Xu Y, et al. N-acetyl L-cysteine protects against cadmium-induced neuronal apoptosis. *Neuropathol Appl Neurobiol.* (2014) 40:759–77. doi: 10.1111/nan.12103

19. Lins TLBG, Gouveia BB, Barberino RS, Silva RLS, Monte APO, Pinto JGC, et al. Rutin prevents cisplatin-induced ovarian damage via antioxidant activity and regulation of PTEN and FOXO3a phosphorylation in mouse model. *Reprod Toxicol.* (2020) 98:209–17. doi: 10.1016/j.reprotox.2020.10.001

20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method. *Methods*. (2001) 25:402-8. doi: 10.1006/meth.2001.1262

21. Chaves A da S, Magalhães NS, Insuela DBR, Silva PMRE, Martins MA, Carvalho VF. Effect of the renin-angiotensin system on the exacerbation of adrenal glucocorticoid steroidogenesis in diabetic mice: Role of angiotensin-II type 2 receptor. *Front Endocrinol (Lausanne).* (2022) 13:1040040. doi: 10.3389/FENDO.2022.1040040

22. Conti V, Izzo V, Corbi G, Russomanno G, Manzo V, De Lise F, et al. Antioxidant supplementation in the treatment of aging-associated diseases. *Front Pharmacol.* (2016) 7:24. doi: 10.3389/fphar.2016.00024

23. Myung S-K, Yang HJ. Efficacy of vitamin and antioxidant supplements in prevention of esophageal cancer: meta-analysis of randomized controlled trials. *J Cancer Prev.* (2013) 18:135–43. doi: 10.15430/JCP.2013.18.2.135

24. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. In: Bjelakovic G, editor. *Cochrane Database of Systematic Reviews.* John Wiley & Sons, Ltd, Chichester, UK (2008). doi: 10.1002/14651858.CD007176

25. Macpherson H, Pipingas A, Pase MP. Multivitamin-multimineral supplementation and mortality: a meta-analysis of randomized controlled trials. *Am J Clin Nutr.* (2013) 97:437–44. doi: 10.3945/ajcn.112.049304

26. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. *Cochrane Database Systematic Rev.* (2017) 2017:600. doi: 10.1002/14651858.CD000254.pub4

27. Lai T-H, Shieh J-M, Tsou C-J, Wu W-B. Gold nanoparticles induce heme oxygenase-1 expression through Nrf2 activation and Bach1 export in human vascular endothelial cells. *Int J Nanomed*. (2015) 10:5925–39. doi: 10.2147/IJN.S88514

28. Dai G, Vaughn S, Zhang Y, Wang ET, Garcia-Cardena G, Gimbrone MA. Biomechanical forces in atherosclerosis-resistant vascular regions regulate endothelial redox balance via phosphoinositol 3-kinase/Akt-dependent activation of Nrf2. *Circ Res.* (2007) 101:723–33. doi: 10.1161/CIRCRESAHA.107.152942

29. Horie M, Warabi E, Komine S, Oh S, Shoda J. Cytoprotective role of nrf2 in electrical pulse stimulated C2C12 myotube. *PloS One*. (2015) 10:e0144835. doi: 10.1371/journal.pone.0144835

30. Kheir-Eldin AA, Motawi TK, Gad MZ, Abd-ElGawad HM. Protective effect of vitamin E, β -carotene and N-acetylcysteine from the brain oxidative stress induced in rats by lipopolysaccharide. Int J Biochem Cell Biol. (2001) 33:475–82. doi: 10.1016/S1357-2725(01)00032-2

31. Repetto EM, Wiszniewski M, Bonelli AL, Vecino CV, Martinez Calejman C, Arias P, et al. Impaired HPA axis function in diabetes involves adrenal apoptosis and phagocytosis. *Endocrine*. (2019) 63:602–14. doi: 10.1007/s12020-018-1755-5

32. Astort F, Repetto EM, Calejman CM, Cipelli JM, Sánchez R, Di Gruccio JM, et al. High glucose-induced changes in steroid production in adrenal cells. *Diabetes Metab Res Rev.* (2009) 25:477–86. doi: 10.1002/dmrr.978

33. Keller-Wood M. Hypothalamic-pituitary-adrenal axis—Feedback control. Compr Physiol Wiley. (2015) p:1161–82. doi: 10.1002/cphy.c140065

34. Herman JP, McKlveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, et al. Regulation of the hypothalamic-pituitary-adrenocortical stress response. *Compr Physiol Wiley*. (2016) p:603–21. doi: 10.1002/cphy.c150015

35. Korou L-M, Agrogiannis G, Koros C, Kitraki E, Vlachos IS, Tzanetakou I, et al. Impact of N-acetylcysteine and sesame oil on lipid metabolism and hypothalamicpituitary-adrenal axis homeostasis in middle-aged hypercholesterolemic mice. *Sci Rep.* (2014) 4:6806. doi: 10.1038/srep06806

36. Ramos-Ramírez P, Tliba O. Glucocorticoid receptor β (GR β): beyond its dominant-negative function. Int J Mol Sci. (2021) 22:3649. doi: 10.3390/ijms22073649

37. Kino T, Tiulpakov A, Ichijo T, Chheng L, Kozasa T, Chrousos GP. G protein β interacts with the glucocorticoid receptor and suppresses its transcriptional activity in the nucleus. *J Cell Biol.* (2005) 169:885–96. doi: 10.1083/jcb.200409150

38. Lockett J, Inder WJ, Clifton VL. The glucocorticoid receptor: isoforms, functions, and contribution to glucocorticoid sensitivity. *Endocr Rev.* (2024) 45:593–624. doi: 10.1210/endrev/bnae008

39. Otto C, Reichardt HM, Schütz G. Absence of glucocorticoid receptor- β in mice. J Biol Chem. (1997) 272:26665–8. doi: 10.1074/jbc.272.42.26665

40. Patel GC, Liu Y, Millar JC, Clark AF. Glucocorticoid receptor GR β regulates glucocorticoid-induced ocular hypertension in mice. *Sci Rep.* (2018) 8:862. doi: 10.1038/s41598-018-19262-9

41. Hinds TD, Ramakrishnan S, Cash HA, Stechschulte LA, Heinrich G, Najjar SM, et al. Discovery of glucocorticoid receptor- β in mice with a role in metabolism. *Mol Endocrinol.* (2010) 24:1715–27. doi: 10.1210/me.2009-0411

42. Han A, Marandici A, Monder C. Metabolism of corticosterone in the mouse. Identification of 11 beta, 20 alpha-dihydroxy-3-oxo-4-pregnen-21-oic acid as a major metabolite. *J Biol Chem*. (1983) 258:13703–7. doi: 10.1016/S0021-9258(17) 43974-3

43. Foresti R, Bains SK, Pitchumony TS, de Castro Brás LE, Drago F, Dubois-Randé J-L, et al. Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. *Pharmacol Res.* (2013) 76:132–48. doi: 10.1016/j.phrs.2013.07.010

44. Ndisang JF. Synergistic interaction between heme oxygenase (HO) and nuclear-factor E2- related factor-2 (Nrf2) against oxidative stress in cardiovascular related diseases. *Curr Pharm Des.* (2017) 23:1465–70. doi: 10.2174/13816128236 66170113153818

45. Zhang Q, Liu J, Duan H, Li R, Peng W, Wu C. Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress. *J* Adv Res. (2021) 34:43–63. doi: 10.1016/j.jare.2021.06.023